PAREXEL Consulting

PAREXEL Consulting
Share

PAREXEL Consulting

 •  September 29

BOSTON, September 29, 2017 - PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, announced that Pamplona Capital Management, LLP (“Pamplona”) completed its acquisition of PAREXEL today. Pamplona acquired all outstanding shares of PAREXEL for $88.10 per share in cash....

PAREXEL Consulting

 •  June 19

Features new ForeSite™ clinical trial methodology designed to reliably predict site success BOSTON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical...

PAREXEL Consulting

 •  June 15

Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently BOSTON, June 15, 2017 –PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced a collaboration with Sanofi to advance the use of...

PAREXEL Consulting

 •  November 30, 2016

This presentation will be available to audience members until Monday, August 28, 2017 at 12:00 PM Eastern Daylight Time. Spirometry data is pivotal to assessing primary or secondary outcomes in most respiratory trials, but implementation in a clinical trial varies by sponsor and service provider. A significant portion of spirometry data in clinical...